These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1283015)

  • 1. Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients.
    Fritz P; Tuczek HV; Offinger B; Schwarzmann P; Schieszl S; Wu X; Kleine B; Blödorn J; Multhaupt H
    Prog Histochem Cytochem; 1992; 26(1-4):146-58. PubMed ID: 1283015
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques.
    Taylor CR; Shi SR; Chaiwun B; Young L; Imam SA; Cote RJ
    Hum Pathol; 1994 Mar; 25(3):263-70. PubMed ID: 7512074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cytosolic concentrations of cathepsin D in 88 infiltrating ductal breast carcinomas having negative estrogen and progesterone receptors. Correlation with other clinical and biological parameters].
    Ruibal A; Arias J; Lapeña G; García Díez S; Tejerina A
    Rev Esp Med Nucl; 2001 Jun; 20(4):332-3. PubMed ID: 11940423
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
    Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance.
    Layfield LJ; Saria EA; Conlon DH; Kerns BJ
    J Surg Oncol; 1996 Mar; 61(3):177-84. PubMed ID: 8637203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance.
    Dowsett M; Makris A; Ellis P; Johnston SR; Salter J; Detre S; Humphries S; Saccani-Jotti G; Powles TJ; Smith IE
    Ann N Y Acad Sci; 1996 Apr; 784():403-11. PubMed ID: 8651589
    [No Abstract]   [Full Text] [Related]  

  • 12. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
    Henzen-Logmans SC; Fieret EJ; Berns EM; van der Burg ME; Klijn JG; Foekens JA
    Int J Cancer; 1994 May; 57(4):468-72. PubMed ID: 8181851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study.
    Makkink-Nombrado SV; Baak JP; Schuurmans L; Theeuwes JW; van der Aa T
    Anal Cell Pathol; 1995 Apr; 8(3):227-45. PubMed ID: 7547496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
    Nugent A; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Biochem Soc Trans; 1992 Feb; 20(1):82S. PubMed ID: 1353039
    [No Abstract]   [Full Text] [Related]  

  • 17. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
    Rudas M; Gnant MF; Mittlböck M; Neumayer R; Kummer A; Jakesz R; Reiner G; Reiner A
    Breast Cancer Res Treat; 1994; 32(2):165-75. PubMed ID: 7865846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric steroid receptor analysis.
    Schutte B; Scheres HM; De Goeij AF; Rousch MJ; Blijham GH; Bosman FT; Ramaekers FC
    Prog Histochem Cytochem; 1992; 26(1-4):68-76. PubMed ID: 1484969
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative analysis of various biochemical and immunohistochemical methods for evaluating hormone receptors in breast carcinoma].
    Gallo C; Orlassino R; Demarchi A; Vallero P; Vineis C
    Pathologica; 2002 Aug; 94(4):176-80. PubMed ID: 12325415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.